Captrust Financial Advisors Northwest Biotherapeutics Inc Transaction History

Captrust Financial Advisors

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 23, 2022	BUY	$0.63 - $1.91 $7,140 - $21,647	11,334 Added 180.19%	17,624 $11,000
Q3 2021 Nov 16, 2021	SELL	$1.1 - $1.49 $1,650 - $2,235	-1,500 Reduced 19.26%	6,290 $8,000
Q1 2021 May 17, 2021	BUY	$1.32 - $1.63 $3,878 - $4,788	2,938 Added 60.55%	7,790 $12,000
Q4 2020 Feb 16, 2021	BUY	$0.73 - $2.3 $138 - $436	190 Added 4.08%	4,852 $7,000
Q3 2020 Nov 17, 2020	BUY	$0.29 - $0.92 $725 - $2,300	2,500 Added 115.63%	4,662 $3,000
Q2 2020 Aug 14, 2020	BUY	$0.15 - $0.38 $324 - $821	2,162 New	2,162 $1,000
Q4 2019 Feb 14, 2020	SELL	$0.21 - $0.25 $1,260 - $1,500	-6,000 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$0.26 - $0.34 $832 - $1,088	-3,200 Reduced 34.78%	6,000 $2,000
Q1 2019 May 15, 2019	BUY	$0.21 - $0.34 $1,932 - $3,128	9,200 New	9,200 $3,000

674K

Ticker NWBO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 1,037,230,016
Market Cap $290M
Description
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, wh...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.